Saisheng Pharmaceutical announced that in the first half of 2026, it achieved operating income of 181 million yuan, a year-on-year decrease of 8.17%; net loss attributable to shareholders of listed companies was 144 million yuan, a year-on-year decrease of 400.66%; and net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 2.5967 million yuan, a year-on-year decrease of 69.96%. The company plans not to pay cash dividends, bonus shares, and not to use the Provident Fund to increase share capital.

Saisheng Pharmaceutical announced that in the first half of 2026, it achieved operating income of 181 million yuan, a year-on-year decrease of 8.17%; net loss attributable to shareholders of listed companies was 144 million yuan, a year-on-year decrease of 400.66%; and net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 2.5967 million yuan, a year-on-year decrease of 69.96%. The company plans not to pay cash dividends, bonus shares, and not to use the Provident Fund to increase share capital.